Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
about
Signatures of selection in fusion transcripts resulting from chromosomal translocations in human cancerScreening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines.Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasmsImatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation statusClonal hypereosinophilic syndrome: two cases report in black men from sub-saharan Africa and literature reviews.Melphalan: old and new uses of a still master drug for multiple myeloma.A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33)Molecular diagnosis of myeloproliferative neoplasms.Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein.Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.Myeloid and lymphoid neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges.Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
P2860
Q33417270-5D0CF258-D02A-4C27-8C3E-8FFB3424F2EBQ33829070-5860A912-9705-43F2-ACF3-3E963E54CBC0Q34539833-D5EBC45E-B63B-4D78-850A-6D660D98A2EEQ35127960-768528B9-24F1-475E-8193-FB479437E389Q35575492-33C69CA3-DF8E-4AB2-A0CE-2F12CCE7A383Q35579165-4E90468E-9F59-4E1B-B151-94EC693BAF21Q36916889-69D43C8E-D3F6-4650-89C8-F92AE02D9E99Q37239587-153B8F55-8815-478A-85D7-3B3F8C1985AFQ37542270-7B39E7CB-6CBA-4EA4-B133-3C512C4A6A59Q37992835-9809E09E-1300-4D75-AD5C-1E2AE0ED8916Q38110527-4890F9A2-2512-4882-A9A9-B26628D4A84BQ38358282-33088E0F-2263-49C9-8193-EA802A9FB7FCQ39139762-8553552B-A1B9-484C-8B4B-21FB727D86FBQ39267824-FD982B40-F74E-4CB8-82D3-B8807E5CE988Q39738130-A9F62DFD-463B-45B5-80BF-6A97C9F77079Q40115606-9593956D-267D-4A51-B7AC-744A1FDBBB74Q41230339-6A60D56E-0375-4315-A78E-5DB2D772DD6BQ44094155-0BB9DDE0-138A-4568-8868-1C0A9F4C6527Q45058347-A79BBF17-5F47-4B1C-AAD1-616567D56817Q46476524-100C23E7-F7E1-4A92-8968-63DD97391B72Q51246186-09A5DA79-9FB9-46D1-B8B0-22D53CC04FB5Q52887806-37DFBFC8-66A6-42BE-A92B-2BE9878A965CQ53289961-9C5540D2-47BC-4EE1-8746-0948FDCD1DA2Q53350377-1F242B59-5DA5-4B5C-9E45-34C02D4C8099Q54510843-6F8528FE-066F-46B4-AF18-20C8CCD1E7CD
P2860
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Characterization of three new ...... wth factor receptor beta gene.
@en
Characterization of three new ...... wth factor receptor beta gene.
@nl
type
label
Characterization of three new ...... wth factor receptor beta gene.
@en
Characterization of three new ...... wth factor receptor beta gene.
@nl
prefLabel
Characterization of three new ...... wth factor receptor beta gene.
@en
Characterization of three new ...... wth factor receptor beta gene.
@nl
P2093
P50
P356
P1433
P1476
Characterization of three new ...... wth factor receptor beta gene.
@en
P2093
Andreas Reiter
Annette Schmitt-Graeff
Christoph Walz
Otto Prümmer
Rüdiger Hehlmann
Stefan Rauh
Volker Hagen
P304
P356
10.3324/HAEMATOL.10980
P577
2007-02-01T00:00:00Z